Skip to content

Study · Animal study (in vivo) · mouse · 2007

3 results

A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice.

Hatziieremia S, Kostomitsopoulos N, Balafas V, Tamvakopoulos C

Rapid communications in mass spectrometry : RCM1 Jan 2007Cited by 13 (Europe PMC)

PMID17610239 (opens in a new tab)DOI10.1002/rcm.3106 (opens in a new tab)PepBankPUB-17610239
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice given melanotan II 1 mg/kg intraperitoneally, clearance of the peptide from plasma was rapid.

    In plain wordsIn mice, melanotan II cleared quickly from the blood after an injection into the abdomen.

    Peptide
    Melanotan II
    Outcome
    Not applicablePlasma clearance of MT-II
    Study

    mousen: not reported in source

    mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Following administration of MT-II, clearance from plasma was rapid.
    1 context sentence
    Summary · context
    following intraperitoneal (ip) administration of 1 mg/kg of peptide in mice.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In mice given melanotan II 1 mg/kg intraperitoneally, brain homogenate held low concentrations (11.4 +/- 5.5 ng/g) at 30 min, which was low compared with plasma, so brain penetration was low.

    In plain wordsIn mice, only small amounts of melanotan II reached the brain compared with the blood.

    Peptide
    Melanotan II
    Outcome
    Not applicableBrain concentration of MT-II at 30 min
    Study

    mousen: not reported in source

    mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 mg/kg · intraperitonealAs given in this study (mouse).

    Measurements

    Brain concentration
    11.4 ng/g
    brain homogenate, 30 min after dosing

    Source sentences

    Summary
    The sensitivity of the assay allowed the determination of low concentrations of MT-II (11.4 +/- 5.5 ng/g) in brain homogenate at 30 min after dosing. However, the brain concentrations when compared with the high plasma levels of MT-II at the same time point confirmed the low penetrability of the peptide in mouse brain.
    1 context sentence
    Summary · context
    following intraperitoneal (ip) administration of 1 mg/kg of peptide in mice.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Other

    An LC/MS/MS method quantified melanotan II in mouse plasma and brain with lower limits of quantification of 0.5 ng/mL and 2.5 ng/g.

    In plain wordsIn mice, a lab method measured melanotan II in plasma and brain at very low concentrations.

    Peptide
    Melanotan II
    Outcome
    Not applicableLC/MS/MS assay lower limit of quantification
    Study

    mousen: not reported in source

    mice
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    LLOQ
    0.5 ng/mL
    plasma (50 microL)
    LLOQ
    2.5 ng/g
    brain homogenate (100 microL)

    Source sentences

    Summary
    The lower limits of quantification (LLOQs) of 0.5 ng/mL and 2.5 ng/g were obtained in 50 microL plasma and 100 microL brain homogenate, respectively.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.